In recent years, there has been a major influx of new genetic tests that have hit the market. While these tests promise to revolutionize diagnostics and treatment decision-making, the industry needs to overcome a variety of reimbursement and logistical barriers to achieve any goals for genomics at scale.
In this episode, guest host and Advisory Board expert partner Devin Airey invites Mark Gardner, the SVP of Genomic Medicine and Oncology at Quest Diagnostics, and Dan Edelstein, President and CEO of Haystack Oncology, to discuss their vision for genomics at scale. Throughout the conversation, they discuss increased attention from providers and purchasers, how to integrate new genomics technology into patient care, and how to address opportunities and concerns in the market.
- 6 questions shaping the future of oncology screening and diagnostics
- What liquid biopsies could mean for cancer treatment and disease monitoring
- Home | Quest Diagnostics
- Haystack Oncology – Better decisions with better MRD testing
- Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio